{"transactions":[{"id":750134,"issuer":{"id":6658,"kind":"organization","name":"Cibus, Inc."},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right-to-Buy)","published_at":"2026-06-04T21:43:22.000Z","date":"2026-06-02","kind":"grant","planned":false,"acquired":true,"shares":77586,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options vest in full, subject to the Director's continued service, the earlier of (1) the first anniversary of the grant date and (2) the date of the Company's next annual meeting of shareholders."}],"balance_after":77586,"derivative":{"exercise_price":1.39,"exercise_date":"2027-06-02","expiration_date":"2036-06-02","underlying":"Class A Common Stock","underlying_shares":77586},"source":{"system":"sec-edgar","filing":"0001615594-26-000042","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000161559426000042/primary_doc.xml","form_type":"4"}},{"id":925720,"issuer":{"id":6658,"kind":"organization","name":"Cibus, Inc."},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2026-02-03T01:27:33.000Z","date":"2026-01-29","kind":"grant","planned":false,"acquired":true,"shares":333333,"price":1.5,"value":499999.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 29, 2026, Cibus, Inc. (the \"Issuer\") entered into an Underwriting Agreement (the \"Underwriting Agreement\") in connection with a firm commitment underwritten public offering (the \"Offering\"), which closed on January 30, 2026. The reporting person purchased 333,333 shares of Class A Common Stock in the Offering at the public offering price of $1.50 per share. The transaction was approved by the Issuer's board of directors in accordance with Rule 16b-3."}],"balance_after":14916640,"source":{"system":"sec-edgar","filing":"0001193125-26-034092","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000119312526034092/ownership.xml","form_type":"4"}},{"id":1115574,"issuer":{"id":6658,"kind":"organization","name":"Cibus, Inc."},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant (right to buy)","published_at":"2025-06-11T21:11:05.000Z","date":"2025-06-09","kind":"other","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pre-funded warrants to purchase Class A Common Stock held by the reporting person have no expiration date."}],"balance_after":0,"derivative":{"exercise_price":0.01,"exercise_date":"2023-12-11","underlying":"Class A Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000950170-25-084928","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000095017025084928/ownership.xml","form_type":"4"}},{"id":1115573,"issuer":{"id":6658,"kind":"organization","name":"Cibus, Inc."},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant (right to buy)","published_at":"2025-06-11T21:11:05.000Z","date":"2025-06-09","kind":"other","planned":false,"acquired":false,"shares":4000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pre-funded warrants to purchase Class A Common Stock held by the reporting person have no expiration date."}],"balance_after":0,"derivative":{"exercise_price":0.0001,"exercise_date":"2025-01-21","underlying":"Class A Common Stock","underlying_shares":4000000},"source":{"system":"sec-edgar","filing":"0000950170-25-084928","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000095017025084928/ownership.xml","form_type":"4"}},{"id":1115572,"issuer":{"id":6658,"kind":"organization","name":"Cibus, Inc."},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2025-06-11T21:11:05.000Z","date":"2025-06-09","kind":"other","planned":false,"acquired":true,"shares":50000,"price":0.01,"value":500.0,"ownership":{"direct":true},"balance_after":14583307,"source":{"system":"sec-edgar","filing":"0000950170-25-084928","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000095017025084928/ownership.xml","form_type":"4"}},{"id":1115571,"issuer":{"id":6658,"kind":"organization","name":"Cibus, Inc."},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2025-06-11T21:11:05.000Z","date":"2025-06-09","kind":"other","planned":false,"acquired":true,"shares":4000000,"price":0.0001,"value":400.0,"ownership":{"direct":true},"balance_after":14533307,"source":{"system":"sec-edgar","filing":"0000950170-25-084928","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000095017025084928/ownership.xml","form_type":"4"}},{"id":1116853,"issuer":{"id":6658,"kind":"organization","name":"Cibus, Inc."},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2025-06-10T20:15:05.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":5714286,"price":1.75,"value":10000000.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On June 5, 2025, Cibus, Inc. (the \"Issuer\") entered into a Securities Purchase Agreement (the \"Purchase  Agreement\") with Rory Riggs, the Chairman of the Company's Board of directors, in connection with a public offering conducted on a reasonable \"best efforts\" basis (the \"Offering\"). Pursuant to the Purchase Agreement, the Issuer agreed to issue and sell to Mr. Riggs 5,714,286 shares of Class A Common Stock, par value $0.0001 per share, at the public offering price of $1.75 per share. The Offering is expected to be fully consummated on or about June 9, 2025.  The transaction was approved by the Issuer's board of directors in accordance with Rule 16b-3."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects corrections with respect to 20,891 shares of Class A Common Stock that were previously reported as attributable directly to the reporting person that are instead held indirectly through the Rory Riggs Family Trust."}],"balance_after":10533307,"source":{"system":"sec-edgar","filing":"0000950170-25-084320","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000095017025084320/ownership.xml","form_type":"4"}},{"id":1134065,"issuer":{"id":6658,"kind":"organization","name":"Cibus, Inc."},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right-to-Buy)","published_at":"2025-05-27T19:07:17.000Z","date":"2025-05-22","kind":"grant","planned":false,"acquired":true,"shares":39301,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options vest in full, subject to the Director's continued service, the earlier of (1) the first anniversary of the grant date and (2) the date of the Company's next annual meeting of the shareholders"}],"balance_after":39301,"derivative":{"exercise_price":2.77,"exercise_date":"2026-05-22","expiration_date":"2035-05-22","underlying":"Class A Common Stock","underlying_shares":39301},"source":{"system":"sec-edgar","filing":"0001615594-25-000073","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000161559425000073/primary_doc.xml","form_type":"4"}},{"id":1184601,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-04-02T21:47:21.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2951,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit (each, a \"Company RSU\") represented a contingent right to receive one Company Share."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Not applicable."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2951},"source":{"system":"sec-edgar","filing":"0000950170-25-049648","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000095017025049648/ownership.xml","form_type":"4"}},{"id":1184600,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-02T21:47:21.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4322,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":67.77,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":4322},"source":{"system":"sec-edgar","filing":"0000950170-25-049648","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000095017025049648/ownership.xml","form_type":"4"}},{"id":1184599,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-02T21:47:21.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7009,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":63.79,"expiration_date":"2033-06-22","underlying":"Common Stock","underlying_shares":7009},"source":{"system":"sec-edgar","filing":"0000950170-25-049648","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000095017025049648/ownership.xml","form_type":"4"}},{"id":1184598,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-02T21:47:21.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16757,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":55.48,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":16757},"source":{"system":"sec-edgar","filing":"0000950170-25-049648","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000095017025049648/ownership.xml","form_type":"4"}},{"id":1184597,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-02T21:47:21.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":43.45,"expiration_date":"2031-06-20","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-25-049648","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000095017025049648/ownership.xml","form_type":"4"}},{"id":1184596,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-02T21:47:21.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":12.45,"expiration_date":"2027-06-26","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-25-049648","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000095017025049648/ownership.xml","form_type":"4"}},{"id":1184595,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-02T21:47:21.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":38.35,"expiration_date":"2026-06-13","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-25-049648","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000095017025049648/ownership.xml","form_type":"4"}},{"id":1184594,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-02T21:47:21.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a \"Company Option\")  that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":26.58,"expiration_date":"2025-06-15","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-25-049648","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000095017025049648/ownership.xml","form_type":"4"}},{"id":1184593,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-02T21:47:21.000Z","date":"2025-04-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":131512,"price":132,"value":17359584.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the \"Merger Agreement\"), by and among Intra-Cellular Therapies, Inc. (the \"Company\"), Johnson & Johnson, a New Jersey corporation (\"Parent\"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which, subject to the terms and conditions thereof, Merger Sub merged with and into the Company (the \"Merger\"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) At the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Company Shares\") issued and outstanding immediately prior to the Effective Time (other than certain Company Shares canceled pursuant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the \"Merger Consideration\"), without interest thereon and less any applicable tax withholdings."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the \"Merger Agreement\"), by and among Intra-Cellular Therapies, Inc. (the \"Company\"), Johnson & Johnson, a New Jersey corporation (\"Parent\"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which, subject to the terms and conditions thereof, Merger Sub merged with and into the Company (the \"Merger\"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the \"Effective Time\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) At the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Company Shares\") issued and outstanding immediately prior to the Effective Time (other than certain Company Shares canceled pursuant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the \"Merger Consideration\"), without interest thereon and less any applicable tax withholdings."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-049648","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000095017025049648/ownership.xml","form_type":"4"}},{"id":1296705,"issuer":{"id":6658,"kind":"organization","name":"Cibus, Inc."},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Pre-Funded Warrant","published_at":"2025-01-23T21:19:47.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":4000000,"price":2.4999,"value":9999600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 21, 2025, Cibus, Inc. (the \"Company\") entered into a Securities Purchase Agreement (the \"Purchase Agreement\") with Rory Riggs, the Company's chief executive officer. Pursuant to the Purchase Agreement, the Company agreed to issue and sell to Mr. Riggs 4,000,000 pre-funded warrants to purchase shares of Class A Common Stock, par value $0.0001 (\"Class A Common Stock\"), and an accompanying common warrant to purchase up to 4,000,000 shares of Class A Common Stock at a combined offering price of $2.4999.  The Purchase Agreement was entered into in connection with the Company's registered direct offering, which is expected to be fully consummated on or about January 24, 2025. The transaction was approved by the Issuer's board of directors in accordance with Rule 16b-3."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 21, 2025, Cibus, Inc. (the \"Company\") entered into a Securities Purchase Agreement (the \"Purchase Agreement\") with Rory Riggs, the Company's chief executive officer. Pursuant to the Purchase Agreement, the Company agreed to issue and sell to Mr. Riggs 4,000,000 pre-funded warrants to purchase shares of Class A Common Stock, par value $0.0001 (\"Class A Common Stock\"), and an accompanying common warrant to purchase up to 4,000,000 shares of Class A Common Stock at a combined offering price of $2.4999.  The Purchase Agreement was entered into in connection with the Company's registered direct offering, which is expected to be fully consummated on or about January 24, 2025. The transaction was approved by the Issuer's board of directors in accordance with Rule 16b-3."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pre-Funded Warrants have no expiration date, may be exercised on a one-for-one basis for shares of Class A Common Stock at an exercise price of $0.0001 per share of Class A Common Stock and are exercisable immediately, to the extent that after giving effect to such exercise the Reporting Person would beneficially own, for purposes of Section 13(d) of the Exchange Act, no more than 19.99% of the outstanding shares of Class A Common Stock or the combined voting power of all of the Issuer's outstanding common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pre-Funded Warrants have no expiration date, may be exercised on a one-for-one basis for shares of Class A Common Stock at an exercise price of $0.0001 per share of Class A Common Stock and are exercisable immediately, to the extent that after giving effect to such exercise the Reporting Person would beneficially own, for purposes of Section 13(d) of the Exchange Act, no more than 19.99% of the outstanding shares of Class A Common Stock or the combined voting power of all of the Issuer's outstanding common stock."}],"balance_after":4000000,"derivative":{"exercise_price":0.0001,"underlying":"Class A Common Stock","underlying_shares":4000000},"source":{"system":"sec-edgar","filing":"0000950170-25-008350","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000095017025008350/ownership.xml","form_type":"4"}},{"id":1296704,"issuer":{"id":6658,"kind":"organization","name":"Cibus, Inc."},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Warrant","published_at":"2025-01-23T21:19:47.000Z","date":"2025-01-21","kind":"grant","planned":false,"acquired":true,"shares":4000000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 21, 2025, Cibus, Inc. (the \"Company\") entered into a Securities Purchase Agreement (the \"Purchase Agreement\") with Rory Riggs, the Company's chief executive officer. Pursuant to the Purchase Agreement, the Company agreed to issue and sell to Mr. Riggs 4,000,000 pre-funded warrants to purchase shares of Class A Common Stock, par value $0.0001 (\"Class A Common Stock\"), and an accompanying common warrant to purchase up to 4,000,000 shares of Class A Common Stock at a combined offering price of $2.4999.  The Purchase Agreement was entered into in connection with the Company's registered direct offering, which is expected to be fully consummated on or about January 24, 2025. The transaction was approved by the Issuer's board of directors in accordance with Rule 16b-3."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 21, 2025, Cibus, Inc. (the \"Company\") entered into a Securities Purchase Agreement (the \"Purchase Agreement\") with Rory Riggs, the Company's chief executive officer. Pursuant to the Purchase Agreement, the Company agreed to issue and sell to Mr. Riggs 4,000,000 pre-funded warrants to purchase shares of Class A Common Stock, par value $0.0001 (\"Class A Common Stock\"), and an accompanying common warrant to purchase up to 4,000,000 shares of Class A Common Stock at a combined offering price of $2.4999.  The Purchase Agreement was entered into in connection with the Company's registered direct offering, which is expected to be fully consummated on or about January 24, 2025. The transaction was approved by the Issuer's board of directors in accordance with Rule 16b-3."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Common Warrants issued to Mr. Riggs may be exercised on a one-for-one basis for shares of Class A Common Stock at an exercise price of $2.4999 per share of Class A Common Stock, to the extent that after giving effect to such exercise the Reporting Person would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), no more than 19.99% of the outstanding shares of Class A Common Stock or the combined voting power of all of the Company's outstanding common stock. The Common Warrants will not be exercisable until the Company receives certain approvals from its stockholders (the \"Warrant Stockholder Approvals\") required by the applicable rules of the Nasdaq Capital Market. The Common Warrants will expire five years following the date of receipt of the Warrant Stockholder Approvals."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Common Warrants issued to Mr. Riggs may be exercised on a one-for-one basis for shares of Class A Common Stock at an exercise price of $2.4999 per share of Class A Common Stock, to the extent that after giving effect to such exercise the Reporting Person would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), no more than 19.99% of the outstanding shares of Class A Common Stock or the combined voting power of all of the Company's outstanding common stock. The Common Warrants will not be exercisable until the Company receives certain approvals from its stockholders (the \"Warrant Stockholder Approvals\") required by the applicable rules of the Nasdaq Capital Market. The Common Warrants will expire five years following the date of receipt of the Warrant Stockholder Approvals."}],"balance_after":4000000,"derivative":{"exercise_price":2.5,"underlying":"Class A Common Stock","underlying_shares":4000000},"source":{"system":"sec-edgar","filing":"0000950170-25-008350","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000095017025008350/ownership.xml","form_type":"4"}},{"id":1305815,"issuer":{"id":6658,"kind":"organization","name":"Cibus, Inc."},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Cibus Common Unit","published_at":"2025-01-10T14:51:51.000Z","date":"2024-12-31","kind":"exercise","planned":false,"acquired":false,"shares":1388084,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each Common Unit is part of an Up-C Unit, together with a share of Class B Common Stock, with each Up-C Unit exchangeable for shares of Class A Common Stock on a 1-for-1 basis pursuant to the terms of the Exchange Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Exchange Agreement, the reporting person exchanged Up-C Units for the same number of shares of Class A Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each Common Unit is part of an Up-C Unit, together with a share of Class B Common Stock, with each Up-C Unit exchangeable for shares of Class A Common Stock on a 1-for-1 basis pursuant to the terms of the Exchange Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each Common Unit is part of an Up-C Unit, together with a share of Class B Common Stock, with each Up-C Unit exchangeable for shares of Class A Common Stock on a 1-for-1 basis pursuant to the terms of the Exchange Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each Common Unit is part of an Up-C Unit, together with a share of Class B Common Stock, with each Up-C Unit exchangeable for shares of Class A Common Stock on a 1-for-1 basis pursuant to the terms of the Exchange Agreement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Pursuant to the Exchange Agreement, the reporting person exchanged Up-C Units for the same number of shares of Class A Common Stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Each Common Unit is part of an Up-C Unit, together with a share of Class B Common Stock, with each Up-C Unit exchangeable for shares of Class A Common Stock on a 1-for-1 basis pursuant to the terms of the Exchange Agreement."}],"balance_after":0,"derivative":{"underlying":"Class A Common Stock","underlying_shares":1388084},"source":{"system":"sec-edgar","filing":"0001615594-25-000004","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000161559425000004/primary_doc.xml","form_type":"4"}},{"id":1305814,"issuer":{"id":6658,"kind":"organization","name":"Cibus, Inc."},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A Common Stock","published_at":"2025-01-10T14:51:51.000Z","date":"2024-12-31","kind":"exercise","planned":false,"acquired":true,"shares":1388084,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Up-C Units are generally exchangeable for shares of the Issuer's Class A Common Stock on a 1-for-1 basis pursuant to an Exchange Agreement dated May 31, 2023 by and among the Issuer, Cibus Global LLC, and the holders of Up-C Units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Exchange Agreement, the reporting person exchanged Up-C Units for the same number of shares of Class A Common Stock."}],"balance_after":4839912,"source":{"system":"sec-edgar","filing":"0001615594-25-000004","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000161559425000004/primary_doc.xml","form_type":"4"}},{"id":1305813,"issuer":{"id":6658,"kind":"organization","name":"Cibus, Inc."},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class B Common Stock","published_at":"2025-01-10T14:51:51.000Z","date":"2024-12-31","kind":"exercise","planned":false,"acquired":false,"shares":1388084,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each share of Class B Common Stock of Cibus, Inc. is paired with a common unit of Cibus Global LLC, which collectively comprise an Up-C Unit."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Up-C Units are generally exchangeable for shares of the Issuer's Class A Common Stock on a 1-for-1 basis pursuant to an Exchange Agreement dated May 31, 2023 by and among the Issuer, Cibus Global LLC, and the holders of Up-C Units."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001615594-25-000004","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000161559425000004/primary_doc.xml","form_type":"4"}},{"id":1316429,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-03T23:01:03.000Z","date":"2024-12-31","kind":"grant","planned":false,"acquired":true,"shares":215,"price":83.52,"value":17956.8,"ownership":{"direct":true},"balance_after":131512,"source":{"system":"sec-edgar","filing":"0000950170-25-001440","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000095017025001440/ownership.xml","form_type":"4"}},{"id":1387053,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-10-15T22:00:03.000Z","date":"2019-06-18","kind":"exercise","planned":false,"acquired":false,"shares":14189,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On June 18, 2018, the reporting person was granted 14,189 restricted stock units, vesting on the first anniversary of the grant date (June 18, 2019)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On June 18, 2018, the reporting person was granted 14,189 restricted stock units, vesting on the first anniversary of the grant date (June 18, 2019)."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":14189},"source":{"system":"sec-edgar","filing":"0000950170-24-114785","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000095017024114785/ownership.xml","form_type":"4"}},{"id":1387052,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-15T22:00:03.000Z","date":"2019-06-18","kind":"exercise","planned":false,"acquired":true,"shares":14189,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":131297,"source":{"system":"sec-edgar","filing":"0000950170-24-114785","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000095017024114785/ownership.xml","form_type":"4"}},{"id":1395308,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-02T22:01:02.000Z","date":"2024-09-30","kind":"grant","planned":false,"acquired":true,"shares":246,"price":73.17,"value":17999.82,"ownership":{"direct":true},"balance_after":117108,"source":{"system":"sec-edgar","filing":"0000950170-24-111766","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000095017024111766/ownership.xml","form_type":"4"}},{"id":1401884,"issuer":{"id":6658,"kind":"organization","name":"Cibus, Inc."},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A Common Stock","published_at":"2024-09-20T21:48:49.000Z","date":"2024-09-18","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":4,"value":1000000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"On September 18, 2024, the Company entered into an Underwriting Agreement (the \"Underwriting Agreement\") in connection with a firm commitment underwritten public offering (the \"Offering\"), which closed on September 19, 2024.  The reporting person purchased 250,000 shares of Class A Common Stock in the Offering at the public offering price of $4.00."}],"balance_after":3451828,"source":{"system":"sec-edgar","filing":"0000950170-24-108504","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000095017024108504/ownership.xml","form_type":"4"}},{"id":1464036,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-03T00:00:20.000Z","date":"2024-06-28","kind":"grant","planned":false,"acquired":true,"shares":262,"price":68.49,"value":17944.38,"ownership":{"direct":true},"balance_after":116862,"source":{"system":"sec-edgar","filing":"0000950170-24-080986","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000095017024080986/ownership.xml","form_type":"4"}},{"id":1469883,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-25T22:04:54.000Z","date":"2024-06-24","kind":"exercise","planned":false,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"On June 24, 2024, the reporting person exercised options to purchase 20,000 shares of common stock that are expiring on June 30, 2024 and the issuer retained 4,462 shares of common stock to pay the exercise price of the options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on June 30, 2014 and will expire on June 30, 2024. All shares underlying this option have vested."}],"balance_after":0,"derivative":{"exercise_price":16.86,"expiration_date":"2024-06-30","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-24-077468","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000095017024077468/ownership.xml","form_type":"4"}},{"id":1469882,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-06-25T22:04:54.000Z","date":"2024-06-23","kind":"exercise","planned":false,"acquired":false,"shares":1567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On June 23, 2023, the reporting person was granted 1,567 restricted stock units, which vested on the first anniversary of the grant date (June 23, 2024)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On June 23, 2023, the reporting person was granted 1,567 restricted stock units, which vested on the first anniversary of the grant date (June 23, 2024)."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1567},"source":{"system":"sec-edgar","filing":"0000950170-24-077468","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000095017024077468/ownership.xml","form_type":"4"}},{"id":1469881,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-25T22:04:54.000Z","date":"2024-06-24","kind":"sale","planned":false,"acquired":false,"shares":4462,"price":75.57,"value":337193.34,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"On June 24, 2024, the reporting person exercised options to purchase 20,000 shares of common stock that are expiring on June 30, 2024 and the issuer retained 4,462 shares of common stock to pay the exercise price of the options."}],"balance_after":116600,"source":{"system":"sec-edgar","filing":"0000950170-24-077468","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000095017024077468/ownership.xml","form_type":"4"}},{"id":1469880,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-25T22:04:54.000Z","date":"2024-06-24","kind":"exercise","planned":false,"acquired":true,"shares":20000,"price":16.86,"value":337200.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"On June 24, 2024, the reporting person exercised options to purchase 20,000 shares of common stock that are expiring on June 30, 2024 and the issuer retained 4,462 shares of common stock to pay the exercise price of the options."}],"balance_after":121062,"source":{"system":"sec-edgar","filing":"0000950170-24-077468","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000095017024077468/ownership.xml","form_type":"4"}},{"id":1469879,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-25T22:04:54.000Z","date":"2024-06-23","kind":"exercise","planned":false,"acquired":true,"shares":1567,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."}],"balance_after":101062,"source":{"system":"sec-edgar","filing":"0000950170-24-077468","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000095017024077468/ownership.xml","form_type":"4"}},{"id":1476137,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-18T22:02:23.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":4322,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":4322,"derivative":{"exercise_price":67.77,"exercise_date":"2025-06-14","expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":4322},"source":{"system":"sec-edgar","filing":"0000950170-24-075081","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000095017024075081/ownership.xml","form_type":"4"}},{"id":1476136,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-06-18T22:02:23.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":2951,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On June 14, 2024, the reporting person was granted 2,951 restricted stock units, vesting on the first anniversary of the grant date (June 14, 2025)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On June 14, 2024, the reporting person was granted 2,951 restricted stock units, vesting on the first anniversary of the grant date (June 14, 2025)."}],"balance_after":2951,"derivative":{"underlying":"Common Stock","underlying_shares":2951},"source":{"system":"sec-edgar","filing":"0000950170-24-075081","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000095017024075081/ownership.xml","form_type":"4"}},{"id":1479694,"issuer":{"id":6658,"kind":"organization","name":"Cibus, Inc."},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Warrant","published_at":"2024-06-14T10:53:59.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":98040,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Represents the consolidated closing bid price on the Nasdaq Capital Market on June 11, 2024."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 11, 2024, the Company entered into a Securities Purchase Agreement (the \"Purchase Agreement\") with Rory Riggs, the Issuer's chief executive officer. Pursuant to the Purchase Agreement, the Company agreed to issue and sell to Mr. Riggs (i) 98,040 shares of Class A Common Stock and an accompanying common warrant to purchase Class A Common Stock at a combined offering price of $10.20.  The Purchase Agreement was entered into in connection with the Issuer's registered direct offering, which is expected to close with respect to Mr. Riggs on or about June 13, 2024. The transaction was approved by the Issuer's board of directors in accordance with Rule 16b-3."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 11, 2024, the Company entered into a Securities Purchase Agreement (the \"Purchase Agreement\") with Rory Riggs, the Issuer's chief executive officer. Pursuant to the Purchase Agreement, the Company agreed to issue and sell to Mr. Riggs (i) 98,040 shares of Class A Common Stock and an accompanying common warrant to purchase Class A Common Stock at a combined offering price of $10.20.  The Purchase Agreement was entered into in connection with the Issuer's registered direct offering, which is expected to close with respect to Mr. Riggs on or about June 13, 2024. The transaction was approved by the Issuer's board of directors in accordance with Rule 16b-3."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Common Warrants issued to Mr. Riggs will expire on June 13, 2029, may be exercised on a one-for-one basis for shares of Class A Common Stock at an exercise price of $10.07 per share of Class A Common Stock, and are exercisable immediately, to the extent that after giving effect to such exercise the Reporting Person would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding shares of Class A Common Stock or the combined voting power of all of the Company's outstanding common stock."}],"balance_after":98040,"derivative":{"exercise_price":10.07,"exercise_date":"2024-06-13","expiration_date":"2029-06-13","underlying":"Class A Common Stock","underlying_shares":98040},"source":{"system":"sec-edgar","filing":"0000950170-24-073319","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000095017024073319/ownership.xml","form_type":"4"}},{"id":1479693,"issuer":{"id":6658,"kind":"organization","name":"Cibus, Inc."},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A Common Stock","published_at":"2024-06-14T10:53:59.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":98040,"price":10.2,"value":1000008.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On June 11, 2024, the Company entered into a Securities Purchase Agreement (the \"Purchase Agreement\") with Rory Riggs, the Issuer's chief executive officer. Pursuant to the Purchase Agreement, the Company agreed to issue and sell to Mr. Riggs (i) 98,040 shares of Class A Common Stock and an accompanying common warrant to purchase Class A Common Stock at a combined offering price of $10.20.  The Purchase Agreement was entered into in connection with the Issuer's registered direct offering, which is expected to close with respect to Mr. Riggs on or about June 13, 2024. The transaction was approved by the Issuer's board of directors in accordance with Rule 16b-3."}],"balance_after":3201828,"source":{"system":"sec-edgar","filing":"0000950170-24-073319","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000095017024073319/ownership.xml","form_type":"4"}},{"id":1554614,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-02T20:15:13.000Z","date":"2024-03-31","kind":"grant","planned":false,"acquired":true,"shares":260,"price":69.2,"value":17992.0,"ownership":{"direct":true},"balance_after":99495,"source":{"system":"sec-edgar","filing":"0000950170-24-040165","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000095017024040165/ownership.xml","form_type":"4"}},{"id":1564103,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-03-22T20:12:23.000Z","date":"2024-03-20","kind":"exercise","planned":false,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 21, 2014, the reporting person was granted options to purchase 20,000 shares of common stock, vesting as to 50% of the shares on January 8, 2015 and as to the remainder of the shares on January 8, 2016."}],"balance_after":0,"derivative":{"exercise_price":18.56,"expiration_date":"2024-03-21","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000950170-24-035358","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000095017024035358/ownership.xml","form_type":"4"}},{"id":1564102,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-22T20:12:23.000Z","date":"2024-03-20","kind":"exercise","planned":false,"acquired":true,"shares":20000,"price":18.56,"value":371200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 20, 2024, the reporting person exercised options to purchase 20,000 shares of common stock that were expiring on March 21, 2024."}],"balance_after":99235,"source":{"system":"sec-edgar","filing":"0000950170-24-035358","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000095017024035358/ownership.xml","form_type":"4"}},{"id":1626261,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2024-02-23T00:23:26.000Z","date":"2024-02-20","kind":"exercise","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with the exchange."},{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with the exchange."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."}],"balance_after":270000,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001802768-24-000014","document":"wk-form4_1708647785.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000180276824000014/wk-form4_1708647785.xml","form_type":"4"}},{"id":1626260,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2024-02-23T00:23:26.000Z","date":"2024-02-20","kind":"exercise","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with the exchange."}],"balance_after":320099,"source":{"system":"sec-edgar","filing":"0001802768-24-000014","document":"wk-form4_1708647785.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000180276824000014/wk-form4_1708647785.xml","form_type":"4"}},{"id":1688996,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2024-01-04T22:16:33.000Z","date":"2024-01-04","kind":"sale","planned":true,"acquired":false,"shares":35702,"price":27.5476,"value":983504.4152,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.36 to $27.79 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":20099,"source":{"system":"sec-edgar","filing":"0001802768-24-000002","document":"wk-form4_1704406578.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000180276824000002/wk-form4_1704406578.xml","form_type":"4"}},{"id":1688995,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2024-01-04T22:16:33.000Z","date":"2024-01-03","kind":"sale","planned":true,"acquired":false,"shares":199098,"price":27.7867,"value":5532276.3966,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.48 to $28.26 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":55801,"source":{"system":"sec-edgar","filing":"0001802768-24-000002","document":"wk-form4_1704406578.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000180276824000002/wk-form4_1704406578.xml","form_type":"4"}},{"id":1688994,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2024-01-04T22:16:33.000Z","date":"2024-01-02","kind":"sale","planned":true,"acquired":false,"shares":235200,"price":28.5165,"value":6707080.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.97 to $28.79 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":254899,"source":{"system":"sec-edgar","filing":"0001802768-24-000002","document":"wk-form4_1704406578.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000180276824000002/wk-form4_1704406578.xml","form_type":"4"}},{"id":1694063,"issuer":{"id":6658,"kind":"organization","name":"Cibus, Inc."},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Cibus Common Units","published_at":"2024-01-04T00:08:08.000Z","date":"2023-12-29","kind":"exercise","planned":false,"acquired":false,"shares":1500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Each Common Unit is part of an Up-C Unit, together with a share of Class B Common Stock, with each Up-C Unit exchangeable for shares of Class A Common Stock on a one-for-one basis pursuant to the terms of the Exchange Agreement."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Reflects the Reporting Person Exchange, which resulted solely in a change in the form of the Reporting Person's aggregate beneficial ownership."},{"field":"shares","element":"transactionShares","label":"F4","text":"Reflects the Reporting Person Exchange, which resulted solely in a change in the form of the Reporting Person's aggregate beneficial ownership."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the Reporting Person Exchange, which resulted solely in a change in the form of the Reporting Person's aggregate beneficial ownership."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Each Common Unit is part of an Up-C Unit, together with a share of Class B Common Stock, with each Up-C Unit exchangeable for shares of Class A Common Stock on a one-for-one basis pursuant to the terms of the Exchange Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Each Common Unit is part of an Up-C Unit, together with a share of Class B Common Stock, with each Up-C Unit exchangeable for shares of Class A Common Stock on a one-for-one basis pursuant to the terms of the Exchange Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"Includes 1,361,226 Common Units, as part of Up-C Units, previously reported by the Reporting Person and 5,967 Common Units, as part of the Up-C Units received in the Distribution and not exchanged in the Reporting Person Exchange."}],"balance_after":1367193,"derivative":{"underlying":"Class A Common Stock","underlying_shares":1500000},"source":{"system":"sec-edgar","filing":"0000899243-24-000057","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000089924324000057/doc4.xml","form_type":"4"}},{"id":1694062,"issuer":{"id":6658,"kind":"organization","name":"Cibus, Inc."},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Cibus Common Units","published_at":"2024-01-04T00:08:08.000Z","date":"2023-12-29","kind":"other","planned":false,"acquired":true,"shares":1505967,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Each Common Unit is part of an Up-C Unit, together with a share of Class B Common Stock, with each Up-C Unit exchangeable for shares of Class A Common Stock on a one-for-one basis pursuant to the terms of the Exchange Agreement."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each share of the Issuer's Class B Common Stock, par value $0.0001 (the \"Class B Common Stock\") is paired with a common unit (the \"Common Units\") of Cibus Global, LLC (\"Cibus Global\"), which collectively comprise an \"Up-C Unit.\"  The Up-C Units are generally exchangeable for shares of Class A Common Stock on a one-for-one basis pursuant to the terms of the Exchange Agreement (the \"Exchange Agreement\"), dated May 31, 2023, by and among the Issuer, Cibus Global, and the holders of Up-C Units. On December 29, 2023, New Ventures Agtech Solutions, LLC (\"New Ventures\") completed a distribution to the Reporting Person of 1,505,967 Up-C Units (the \"Distribution\").  Such Up-C Units were previously reported as indirectly attributable to the Reporting Person as a result of the Reporting Person having shared voting and investment power in respect of New Ventures and the other investors in New Ventures."},{"field":"kind","element":"transactionCoding","label":"F3","text":"(Continued from Footnote 2) Simultaneously with the Distribution, the Reporting Person exchanged 1,500,000 shares of such Up-C Units for 1,500,000 shares of Class A Common Stock (the \"Reporting Person Exchange\") in accordance with the Exchange Agreement,  Accordingly, although the Reporting Person's aggregate beneficial ownership has not changed, this Form reports the change in the Reporting Person's beneficial ownership both in name and form."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Each Common Unit is part of an Up-C Unit, together with a share of Class B Common Stock, with each Up-C Unit exchangeable for shares of Class A Common Stock on a one-for-one basis pursuant to the terms of the Exchange Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Each Common Unit is part of an Up-C Unit, together with a share of Class B Common Stock, with each Up-C Unit exchangeable for shares of Class A Common Stock on a one-for-one basis pursuant to the terms of the Exchange Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Each Common Unit is part of an Up-C Unit, together with a share of Class B Common Stock, with each Up-C Unit exchangeable for shares of Class A Common Stock on a one-for-one basis pursuant to the terms of the Exchange Agreement."}],"balance_after":2867193,"derivative":{"underlying":"Class A Common Stock","underlying_shares":1505967},"source":{"system":"sec-edgar","filing":"0000899243-24-000057","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000089924324000057/doc4.xml","form_type":"4"}},{"id":1694061,"issuer":{"id":6658,"kind":"organization","name":"Cibus, Inc."},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A Common Stock","published_at":"2024-01-04T00:08:08.000Z","date":"2023-12-29","kind":"exercise","planned":false,"acquired":true,"shares":1500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Reflects the Reporting Person Exchange, which resulted solely in a change in the form of the Reporting Person's aggregate beneficial ownership."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the Reporting Person Exchange, which resulted solely in a change in the form of the Reporting Person's aggregate beneficial ownership."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Includes 1,603,788 shares of Class A Common Stock previously reported by the Reporting Person and 1,500,000 shares of Class A Common Stock received pursuant to the Reporting Person Exchange."}],"balance_after":3103788,"source":{"system":"sec-edgar","filing":"0000899243-24-000057","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000089924324000057/doc4.xml","form_type":"4"}},{"id":1694060,"issuer":{"id":6658,"kind":"organization","name":"Cibus, Inc."},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class B Common Stock","published_at":"2024-01-04T00:08:08.000Z","date":"2023-12-29","kind":"exercise","planned":false,"acquired":false,"shares":1500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Reflects the Reporting Person Exchange, which resulted solely in a change in the form of the Reporting Person's aggregate beneficial ownership."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the Reporting Person Exchange, which resulted solely in a change in the form of the Reporting Person's aggregate beneficial ownership."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes 1,361,226 shares of Class B Common Stock, as part of Up-C Units, previously reported by the Reporting Person and 5,967 shares of Class B Common Stock, as part of the Up-C Units received in the Distribution and not exchanged in the Reporting Person Exchange."}],"balance_after":1367193,"source":{"system":"sec-edgar","filing":"0000899243-24-000057","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000089924324000057/doc4.xml","form_type":"4"}},{"id":1694059,"issuer":{"id":6658,"kind":"organization","name":"Cibus, Inc."},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class B Common Stock","published_at":"2024-01-04T00:08:08.000Z","date":"2023-12-29","kind":"other","planned":false,"acquired":true,"shares":1505967,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Each share of the Issuer's Class B Common Stock, par value $0.0001 (the \"Class B Common Stock\") is paired with a common unit (the \"Common Units\") of Cibus Global, LLC (\"Cibus Global\"), which collectively comprise an \"Up-C Unit.\"  The Up-C Units are generally exchangeable for shares of Class A Common Stock on a one-for-one basis pursuant to the terms of the Exchange Agreement (the \"Exchange Agreement\"), dated May 31, 2023, by and among the Issuer, Cibus Global, and the holders of Up-C Units. On December 29, 2023, New Ventures Agtech Solutions, LLC (\"New Ventures\") completed a distribution to the Reporting Person of 1,505,967 Up-C Units (the \"Distribution\").  Such Up-C Units were previously reported as indirectly attributable to the Reporting Person as a result of the Reporting Person having shared voting and investment power in respect of New Ventures and the other investors in New Ventures."},{"field":"kind","element":"transactionCoding","label":"F3","text":"(Continued from Footnote 2) Simultaneously with the Distribution, the Reporting Person exchanged 1,500,000 shares of such Up-C Units for 1,500,000 shares of Class A Common Stock (the \"Reporting Person Exchange\") in accordance with the Exchange Agreement,  Accordingly, although the Reporting Person's aggregate beneficial ownership has not changed, this Form reports the change in the Reporting Person's beneficial ownership both in name and form."}],"balance_after":2867193,"source":{"system":"sec-edgar","filing":"0000899243-24-000057","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000089924324000057/doc4.xml","form_type":"4"}},{"id":1694058,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-03T23:46:09.000Z","date":"2023-12-31","kind":"grant","planned":false,"acquired":true,"shares":251,"price":71.62,"value":17976.62,"ownership":{"direct":true},"balance_after":79235,"source":{"system":"sec-edgar","filing":"0000950170-24-001305","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000095017024001305/ownership.xml","form_type":"4"}},{"id":1711403,"issuer":{"id":6658,"kind":"organization","name":"Cibus, Inc."},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Pre-Funded Warrant","published_at":"2023-12-14T22:10:06.000Z","date":"2023-12-12","kind":"other","planned":false,"acquired":true,"shares":50000,"price":10.57,"value":528500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On December 11, 2023, the Issuer entered into an Underwriting Agreement with Stifel, Nicolaus & Company, Incorporated and Canaccord Genuity LLC, as underwriters in respect of an underwritten registered direct offering (the \"Underwritten Offering\"). Pursuant to the Underwritten Offering, the underwriters placed (i) 517,107 shares of Class A Common Stock to Mr. Riggs at a purchase price of $10.58; (ii) 2,106,723 shares of Class A Common Stock to certain other investors at a purchase price of $9.00; and (iii) 50,000 Pre-Funded Warrants to purchase 50,000 shares of Class A Common Stock (\"Pre-Funded Warrants\") to Mr. Riggs at a purchase price of $10.57 per Pre-Funded Warrant. On December 14, 2023, the Issuer consummated the Underwritten Offering."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On December 11, 2023, the Issuer entered into an Underwriting Agreement with Stifel, Nicolaus & Company, Incorporated and Canaccord Genuity LLC, as underwriters in respect of an underwritten registered direct offering (the \"Underwritten Offering\"). Pursuant to the Underwritten Offering, the underwriters placed (i) 517,107 shares of Class A Common Stock to Mr. Riggs at a purchase price of $10.58; (ii) 2,106,723 shares of Class A Common Stock to certain other investors at a purchase price of $9.00; and (iii) 50,000 Pre-Funded Warrants to purchase 50,000 shares of Class A Common Stock (\"Pre-Funded Warrants\") to Mr. Riggs at a purchase price of $10.57 per Pre-Funded Warrant. On December 14, 2023, the Issuer consummated the Underwritten Offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pre-Funded Warrants have no expiration date, may be exercised on a one-for-one basis for shares of Class A Common Stock at an exercise price of $0.01 per share of Class A Common Stock and are exercisable immediately, to the extent that after giving effect to such exercise the Reporting Person would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding shares of Class A Common Stock or the combined voting power of all of the Issuer's outstanding common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pre-Funded Warrants have no expiration date, may be exercised on a one-for-one basis for shares of Class A Common Stock at an exercise price of $0.01 per share of Class A Common Stock and are exercisable immediately, to the extent that after giving effect to such exercise the Reporting Person would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding shares of Class A Common Stock or the combined voting power of all of the Issuer's outstanding common stock."}],"balance_after":50000,"derivative":{"exercise_price":0.01,"underlying":"Class A Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000950170-23-070459","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000095017023070459/ownership.xml","form_type":"4"}},{"id":1711402,"issuer":{"id":6658,"kind":"organization","name":"Cibus, Inc."},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A Common Stock","published_at":"2023-12-14T22:10:06.000Z","date":"2023-12-12","kind":"purchase","planned":false,"acquired":true,"shares":517107,"price":10.58,"value":5470992.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On December 11, 2023, the Issuer entered into an Underwriting Agreement with Stifel, Nicolaus & Company, Incorporated and Canaccord Genuity LLC, as underwriters in respect of an underwritten registered direct offering (the \"Underwritten Offering\"). Pursuant to the Underwritten Offering, the underwriters placed (i) 517,107 shares of Class A Common Stock to Mr. Riggs at a purchase price of $10.58; (ii) 2,106,723 shares of Class A Common Stock to certain other investors at a purchase price of $9.00; and (iii) 50,000 Pre-Funded Warrants to purchase 50,000 shares of Class A Common Stock (\"Pre-Funded Warrants\") to Mr. Riggs at a purchase price of $10.57 per Pre-Funded Warrant. On December 14, 2023, the Issuer consummated the Underwritten Offering."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"On December 11, 2023, the Issuer entered into an Underwriting Agreement with Stifel, Nicolaus & Company, Incorporated and Canaccord Genuity LLC, as underwriters in respect of an underwritten registered direct offering (the \"Underwritten Offering\"). Pursuant to the Underwritten Offering, the underwriters placed (i) 517,107 shares of Class A Common Stock to Mr. Riggs at a purchase price of $10.58; (ii) 2,106,723 shares of Class A Common Stock to certain other investors at a purchase price of $9.00; and (iii) 50,000 Pre-Funded Warrants to purchase 50,000 shares of Class A Common Stock (\"Pre-Funded Warrants\") to Mr. Riggs at a purchase price of $10.57 per Pre-Funded Warrant. On December 14, 2023, the Issuer consummated the Underwritten Offering."}],"balance_after":1622495,"source":{"system":"sec-edgar","filing":"0000950170-23-070459","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000095017023070459/ownership.xml","form_type":"4"}},{"id":1711401,"issuer":{"id":6658,"kind":"organization","name":"Cibus, Inc."},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A Common Stock","published_at":"2023-12-14T22:10:06.000Z","date":"2023-09-27","kind":"other","planned":false,"acquired":false,"shares":39476,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 27, 2023, New Ventures Agtech Solutions, LLC effectuated a pro rata distribution to its members (the \"Distribution\") of all of the shares of Class A Common Stock, par value $0.0001 (\"Class A Common Stock\"), of Cibus, Inc. (the \"Issuer\") held by it, which were previously reported as indirectly attributable to the Reporting Person as a result of the Reporting Person having shared voting and investment power in respect of New Ventures Agtech Solutions, LLC.  Pursuant to the Distribution, (i) 63,626 shares of Class A Common Stock were distributed to the Reporting Person; (ii) 15,791 shares of Class A Common Stock were distributed to the Reporting Person's spouse; and (iii) 39,476 shares of Class A Common Stock were distributed to other members of New Ventures Agtech Solutions, LLC (\"Third-Party Member Shares\"), which Third-Party Member Shares the Reporting Person has no beneficial interest in."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On September 27, 2023, New Ventures Agtech Solutions, LLC effectuated a pro rata distribution to its members (the \"Distribution\") of all of the shares of Class A Common Stock, par value $0.0001 (\"Class A Common Stock\"), of Cibus, Inc. (the \"Issuer\") held by it, which were previously reported as indirectly attributable to the Reporting Person as a result of the Reporting Person having shared voting and investment power in respect of New Ventures Agtech Solutions, LLC.  Pursuant to the Distribution, (i) 63,626 shares of Class A Common Stock were distributed to the Reporting Person; (ii) 15,791 shares of Class A Common Stock were distributed to the Reporting Person's spouse; and (iii) 39,476 shares of Class A Common Stock were distributed to other members of New Ventures Agtech Solutions, LLC (\"Third-Party Member Shares\"), which Third-Party Member Shares the Reporting Person has no beneficial interest in."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (i) 5,401 shares of Class A Common Stock held jointly with the reporting person's sibling and (ii) 79,417 shares of Class A Common Stock previously reported as indirectly attributable to the Reporting Person through New Ventures Agtech Solutions, LLC that were acquired by the Reporting Person pursuant to the Distribution, of which 63,626 shares of Class A Common Stock are held directly by the Reporting Person and 15,791 shares of Class A Common Stock are held indirectly through the Reporting Person's spouse."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On September 27, 2023, New Ventures Agtech Solutions, LLC effectuated a pro rata distribution to its members (the \"Distribution\") of all of the shares of Class A Common Stock, par value $0.0001 (\"Class A Common Stock\"), of Cibus, Inc. (the \"Issuer\") held by it, which were previously reported as indirectly attributable to the Reporting Person as a result of the Reporting Person having shared voting and investment power in respect of New Ventures Agtech Solutions, LLC.  Pursuant to the Distribution, (i) 63,626 shares of Class A Common Stock were distributed to the Reporting Person; (ii) 15,791 shares of Class A Common Stock were distributed to the Reporting Person's spouse; and (iii) 39,476 shares of Class A Common Stock were distributed to other members of New Ventures Agtech Solutions, LLC (\"Third-Party Member Shares\"), which Third-Party Member Shares the Reporting Person has no beneficial interest in."}],"balance_after":1105388,"source":{"system":"sec-edgar","filing":"0000950170-23-070459","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000095017023070459/ownership.xml","form_type":"4"}},{"id":1742832,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2023-11-14T22:17:14.000Z","date":"2023-11-13","kind":"exercise","planned":false,"acquired":false,"shares":47559,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with the exchange."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."}],"balance_after":300000,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":47559},"source":{"system":"sec-edgar","filing":"0001802768-23-000030","document":"wk-form4_1700000224.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000180276823000030/wk-form4_1700000224.xml","form_type":"4"}},{"id":1742831,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2023-11-14T22:17:14.000Z","date":"2023-11-13","kind":"exercise","planned":false,"acquired":true,"shares":475590,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with the exchange."}],"balance_after":490099,"source":{"system":"sec-edgar","filing":"0001802768-23-000030","document":"wk-form4_1700000224.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000180276823000030/wk-form4_1700000224.xml","form_type":"4"}},{"id":1770830,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-10-02T21:29:25.000Z","date":"2023-09-30","kind":"grant","planned":false,"acquired":true,"shares":345,"price":52.09,"value":17971.05,"ownership":{"direct":true},"balance_after":78984,"source":{"system":"sec-edgar","filing":"0001209191-23-051140","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000120919123051140/doc4.xml","form_type":"4"}},{"id":1813237,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2023-08-08T21:39:06.000Z","date":"2023-08-08","kind":"gift","planned":false,"acquired":false,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"No limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with an exchange."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Reporting Person made a charitable donation of RPI US LP Interests. No Class A Ordinary Shares or RPI US LP Interests were sold."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."}],"balance_after":347559,"derivative":{"underlying":"Class A Ordinary Shares","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001209191-23-045065","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000120919123045065/doc4.xml","form_type":"4"}},{"id":1837544,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-05T20:30:58.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":279,"price":63.32,"value":17666.28,"ownership":{"direct":true},"balance_after":78639,"source":{"system":"sec-edgar","filing":"0001209191-23-041097","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000120919123041097/doc4.xml","form_type":"4"}},{"id":1843714,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-27T21:11:48.000Z","date":"2023-06-23","kind":"grant","planned":false,"acquired":true,"shares":7009,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":7009,"derivative":{"exercise_price":63.79,"exercise_date":"2024-06-23","expiration_date":"2033-06-22","underlying":"Common Stock","underlying_shares":7009},"source":{"system":"sec-edgar","filing":"0001209191-23-039928","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000120919123039928/doc4.xml","form_type":"4"}},{"id":1843713,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-06-27T21:11:48.000Z","date":"2023-06-23","kind":"grant","planned":false,"acquired":true,"shares":1567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On June 23, 2023, the reporting person was granted 1,567 restricted stock units, vesting on the first anniversary of the grant date (June 23, 2024)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On June 23, 2023, the reporting person was granted 1,567 restricted stock units, vesting on the first anniversary of the grant date (June 23, 2024)."}],"balance_after":1567,"derivative":{"underlying":"Common Stock","underlying_shares":1567},"source":{"system":"sec-edgar","filing":"0001209191-23-039928","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000120919123039928/doc4.xml","form_type":"4"}},{"id":1844550,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2023-06-26T20:14:44.000Z","date":"2023-06-23","kind":"grant","planned":false,"acquired":true,"shares":7747,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the \"Plan\") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder."}],"balance_after":14509,"source":{"system":"sec-edgar","filing":"0001209191-23-039694","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000120919123039694/doc4.xml","form_type":"4"}},{"id":1870792,"issuer":{"id":6658,"kind":"organization","name":"Cibus, Inc."},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Cibus Common Units","published_at":"2023-06-02T11:05:23.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":1505967,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"The Cibus Common Units, together with the Class B Common Stock (collectively, \"Up-C Units\") are generally exchangeable by the reporting person for shares of Class A Common Stock on a one-for-one basis, or, subject to certain restrictions, the cash equivalent with respect to all or a portion thereof, based on a volume-weighted average price of a share of Class A Common Stock pursuant to the terms of the Exchange Agreement, dated May 31, 2023, by and among the Issuer, Cibus, and the Up-C Unit holders."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents Cibus Common Units received as consideration in connection with the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The Cibus Common Units, together with the Class B Common Stock (collectively, \"Up-C Units\") are generally exchangeable by the reporting person for shares of Class A Common Stock on a one-for-one basis, or, subject to certain restrictions, the cash equivalent with respect to all or a portion thereof, based on a volume-weighted average price of a share of Class A Common Stock pursuant to the terms of the Exchange Agreement, dated May 31, 2023, by and among the Issuer, Cibus, and the Up-C Unit holders."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The Cibus Common Units, together with the Class B Common Stock (collectively, \"Up-C Units\") are generally exchangeable by the reporting person for shares of Class A Common Stock on a one-for-one basis, or, subject to certain restrictions, the cash equivalent with respect to all or a portion thereof, based on a volume-weighted average price of a share of Class A Common Stock pursuant to the terms of the Exchange Agreement, dated May 31, 2023, by and among the Issuer, Cibus, and the Up-C Unit holders."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held by New Ventures Agtech Solutions, LLC, for which the reporting person has voting and investment power."}],"balance_after":2888084,"derivative":{"underlying":"Class A Common Stock","underlying_shares":1505967},"source":{"system":"sec-edgar","filing":"0000899243-23-014329","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000089924323014329/doc4.xml","form_type":"4"}},{"id":1870791,"issuer":{"id":6658,"kind":"organization","name":"Cibus, Inc."},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Cibus Common Units","published_at":"2023-06-02T11:05:23.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":20891,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"The Cibus Common Units, together with the Class B Common Stock (collectively, \"Up-C Units\") are generally exchangeable by the reporting person for shares of Class A Common Stock on a one-for-one basis, or, subject to certain restrictions, the cash equivalent with respect to all or a portion thereof, based on a volume-weighted average price of a share of Class A Common Stock pursuant to the terms of the Exchange Agreement, dated May 31, 2023, by and among the Issuer, Cibus, and the Up-C Unit holders."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents Cibus Common Units received as consideration in connection with the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The Cibus Common Units, together with the Class B Common Stock (collectively, \"Up-C Units\") are generally exchangeable by the reporting person for shares of Class A Common Stock on a one-for-one basis, or, subject to certain restrictions, the cash equivalent with respect to all or a portion thereof, based on a volume-weighted average price of a share of Class A Common Stock pursuant to the terms of the Exchange Agreement, dated May 31, 2023, by and among the Issuer, Cibus, and the Up-C Unit holders."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The Cibus Common Units, together with the Class B Common Stock (collectively, \"Up-C Units\") are generally exchangeable by the reporting person for shares of Class A Common Stock on a one-for-one basis, or, subject to certain restrictions, the cash equivalent with respect to all or a portion thereof, based on a volume-weighted average price of a share of Class A Common Stock pursuant to the terms of the Exchange Agreement, dated May 31, 2023, by and among the Issuer, Cibus, and the Up-C Unit holders."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held by the Rory Riggs Family Trust, for which the reporting person is trustee and has sole voting and dispositive power with respect to the shares held by the trust."}],"balance_after":1382117,"derivative":{"underlying":"Class A Common Stock","underlying_shares":20891},"source":{"system":"sec-edgar","filing":"0000899243-23-014329","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000089924323014329/doc4.xml","form_type":"4"}},{"id":1870790,"issuer":{"id":6658,"kind":"organization","name":"Cibus, Inc."},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Cibus Common Units","published_at":"2023-06-02T11:05:23.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":1361226,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"The Cibus Common Units, together with the Class B Common Stock (collectively, \"Up-C Units\") are generally exchangeable by the reporting person for shares of Class A Common Stock on a one-for-one basis, or, subject to certain restrictions, the cash equivalent with respect to all or a portion thereof, based on a volume-weighted average price of a share of Class A Common Stock pursuant to the terms of the Exchange Agreement, dated May 31, 2023, by and among the Issuer, Cibus, and the Up-C Unit holders."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents Cibus Common Units received as consideration in connection with the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The Cibus Common Units, together with the Class B Common Stock (collectively, \"Up-C Units\") are generally exchangeable by the reporting person for shares of Class A Common Stock on a one-for-one basis, or, subject to certain restrictions, the cash equivalent with respect to all or a portion thereof, based on a volume-weighted average price of a share of Class A Common Stock pursuant to the terms of the Exchange Agreement, dated May 31, 2023, by and among the Issuer, Cibus, and the Up-C Unit holders."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The Cibus Common Units, together with the Class B Common Stock (collectively, \"Up-C Units\") are generally exchangeable by the reporting person for shares of Class A Common Stock on a one-for-one basis, or, subject to certain restrictions, the cash equivalent with respect to all or a portion thereof, based on a volume-weighted average price of a share of Class A Common Stock pursuant to the terms of the Exchange Agreement, dated May 31, 2023, by and among the Issuer, Cibus, and the Up-C Unit holders."}],"balance_after":1361226,"derivative":{"underlying":"Class A Common Stock","underlying_shares":1361226},"source":{"system":"sec-edgar","filing":"0000899243-23-014329","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000089924323014329/doc4.xml","form_type":"4"}},{"id":1870789,"issuer":{"id":6658,"kind":"organization","name":"Cibus, Inc."},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class B Common Stock","published_at":"2023-06-02T11:05:23.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":1505967,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents shares of Class B Common Stock received as consideration in connection with the Merger Agreement, with the number of such shares of Class B Common Stock equal to the number of newly issued membership units of Cibus (\"Cibus Common Units\"), received by the reporting person as consideration in connection with the closing of the transactions contemplated Merger Agreement. Shares of Class B Common Stock have full voting, but no economic rights. The Issuer is the managing member of Cibus, with the Issuer's only material asset consisting of Cibus Common Units."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held by New Ventures Agtech Solutions, LLC, for which the reporting person has voting and investment power."}],"balance_after":2888084,"source":{"system":"sec-edgar","filing":"0000899243-23-014329","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000089924323014329/doc4.xml","form_type":"4"}},{"id":1870788,"issuer":{"id":6658,"kind":"organization","name":"Cibus, Inc."},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class B Common Stock","published_at":"2023-06-02T11:05:23.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":20891,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents shares of Class B Common Stock received as consideration in connection with the Merger Agreement, with the number of such shares of Class B Common Stock equal to the number of newly issued membership units of Cibus (\"Cibus Common Units\"), received by the reporting person as consideration in connection with the closing of the transactions contemplated Merger Agreement. Shares of Class B Common Stock have full voting, but no economic rights. The Issuer is the managing member of Cibus, with the Issuer's only material asset consisting of Cibus Common Units."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held by the Rory Riggs Family Trust, for which the reporting person is trustee and has sole voting and dispositive power with respect to the shares held by the trust."}],"balance_after":1382117,"source":{"system":"sec-edgar","filing":"0000899243-23-014329","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000089924323014329/doc4.xml","form_type":"4"}},{"id":1870787,"issuer":{"id":6658,"kind":"organization","name":"Cibus, Inc."},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class B Common Stock","published_at":"2023-06-02T11:05:23.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":1361226,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents shares of Class B Common Stock received as consideration in connection with the Merger Agreement, with the number of such shares of Class B Common Stock equal to the number of newly issued membership units of Cibus (\"Cibus Common Units\"), received by the reporting person as consideration in connection with the closing of the transactions contemplated Merger Agreement. Shares of Class B Common Stock have full voting, but no economic rights. The Issuer is the managing member of Cibus, with the Issuer's only material asset consisting of Cibus Common Units."}],"balance_after":1361226,"source":{"system":"sec-edgar","filing":"0000899243-23-014329","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000089924323014329/doc4.xml","form_type":"4"}},{"id":1870786,"issuer":{"id":6658,"kind":"organization","name":"Cibus, Inc."},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A Common Stock","published_at":"2023-06-02T11:05:23.000Z","date":"2023-06-01","kind":"purchase","planned":false,"acquired":true,"shares":1000,"price":31.5,"value":31500.0,"ownership":{"direct":true},"balance_after":1154464,"source":{"system":"sec-edgar","filing":"0000899243-23-014329","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000089924323014329/doc4.xml","form_type":"4"}},{"id":1870785,"issuer":{"id":6658,"kind":"organization","name":"Cibus, Inc."},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A Common Stock","published_at":"2023-06-02T11:05:23.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":167992,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Gives effect to the 1-for-5 reverse stock split of Calyxt's common stock on May 31, 2023. On the closing date, the closing price of Calyxt's common stock was $6.30. Upon closing, Calyxt was renamed \"Cibus, Inc.\", the Issuer's Amended and Restated Certificate was amended such that the Issuer had two classes of common stock (Class A Common Stock and Class B Common Stock), and Calyxt's existing common stock remained as Class A Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents substitute awards constituting restricted shares of Class A Common Stock granted and issued pursuant to the Cibus, Inc. 2017 Omnibus Incentive Plan upon the closing of the transactions contemplated by the Merger Agreement (the \"Transactions\"), whereby certain Cibus restricted profits interest units previously granted to employees of Cibus were automatically cancelled and converted into the right to receive a number of restricted shares of the Class A Common Stock, subject to the same vesting schedule as was applicable to such profits interests units prior to the closing of the Transactions."}],"balance_after":1153464,"source":{"system":"sec-edgar","filing":"0000899243-23-014329","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000089924323014329/doc4.xml","form_type":"4"}},{"id":1870784,"issuer":{"id":6658,"kind":"organization","name":"Cibus, Inc."},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A Common Stock","published_at":"2023-06-02T11:05:23.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":9600,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of Class A Common Stock received as consideration in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated January 13, 2023, as amended by the First Amendment to the Merger Agreement, dated April 14, 2023 (as amended, the \"Merger Agreement\"), by and among Cibus, Inc. (formerly Calyxt, Inc.) (the \"Issuer\", and prior to the closing of the transactions contemplated by the Merger Agreement, \"Calyxt\"), Calypso Merger Subsidiary, LLC, Cibus Global, LLC (\"Cibus\") and certain blocker entities party thereto."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Gives effect to the 1-for-5 reverse stock split of Calyxt's common stock on May 31, 2023. On the closing date, the closing price of Calyxt's common stock was $6.30. Upon closing, Calyxt was renamed \"Cibus, Inc.\", the Issuer's Amended and Restated Certificate was amended such that the Issuer had two classes of common stock (Class A Common Stock and Class B Common Stock), and Calyxt's existing common stock remained as Class A Common Stock."}],"balance_after":985472,"source":{"system":"sec-edgar","filing":"0000899243-23-014329","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000089924323014329/doc4.xml","form_type":"4"}},{"id":1870783,"issuer":{"id":6658,"kind":"organization","name":"Cibus, Inc."},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A Common Stock","published_at":"2023-06-02T11:05:23.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":5401,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of Class A Common Stock received as consideration in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated January 13, 2023, as amended by the First Amendment to the Merger Agreement, dated April 14, 2023 (as amended, the \"Merger Agreement\"), by and among Cibus, Inc. (formerly Calyxt, Inc.) (the \"Issuer\", and prior to the closing of the transactions contemplated by the Merger Agreement, \"Calyxt\"), Calypso Merger Subsidiary, LLC, Cibus Global, LLC (\"Cibus\") and certain blocker entities party thereto."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Gives effect to the 1-for-5 reverse stock split of Calyxt's common stock on May 31, 2023. On the closing date, the closing price of Calyxt's common stock was $6.30. Upon closing, Calyxt was renamed \"Cibus, Inc.\", the Issuer's Amended and Restated Certificate was amended such that the Issuer had two classes of common stock (Class A Common Stock and Class B Common Stock), and Calyxt's existing common stock remained as Class A Common Stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Held jointly with the reporting person's spouse, Robin Riggs."}],"balance_after":975872,"source":{"system":"sec-edgar","filing":"0000899243-23-014329","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000089924323014329/doc4.xml","form_type":"4"}},{"id":1870782,"issuer":{"id":6658,"kind":"organization","name":"Cibus, Inc."},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A Common Stock","published_at":"2023-06-02T11:05:23.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":118893,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of Class A Common Stock received as consideration in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated January 13, 2023, as amended by the First Amendment to the Merger Agreement, dated April 14, 2023 (as amended, the \"Merger Agreement\"), by and among Cibus, Inc. (formerly Calyxt, Inc.) (the \"Issuer\", and prior to the closing of the transactions contemplated by the Merger Agreement, \"Calyxt\"), Calypso Merger Subsidiary, LLC, Cibus Global, LLC (\"Cibus\") and certain blocker entities party thereto."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Gives effect to the 1-for-5 reverse stock split of Calyxt's common stock on May 31, 2023. On the closing date, the closing price of Calyxt's common stock was $6.30. Upon closing, Calyxt was renamed \"Cibus, Inc.\", the Issuer's Amended and Restated Certificate was amended such that the Issuer had two classes of common stock (Class A Common Stock and Class B Common Stock), and Calyxt's existing common stock remained as Class A Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held by New Ventures Agtech Solutions, LLC, for which the reporting person has voting and investment power."}],"balance_after":970471,"source":{"system":"sec-edgar","filing":"0000899243-23-014329","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000089924323014329/doc4.xml","form_type":"4"}},{"id":1870781,"issuer":{"id":6658,"kind":"organization","name":"Cibus, Inc."},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A Common Stock","published_at":"2023-06-02T11:05:23.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":2916,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of Class A Common Stock received as consideration in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated January 13, 2023, as amended by the First Amendment to the Merger Agreement, dated April 14, 2023 (as amended, the \"Merger Agreement\"), by and among Cibus, Inc. (formerly Calyxt, Inc.) (the \"Issuer\", and prior to the closing of the transactions contemplated by the Merger Agreement, \"Calyxt\"), Calypso Merger Subsidiary, LLC, Cibus Global, LLC (\"Cibus\") and certain blocker entities party thereto."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Gives effect to the 1-for-5 reverse stock split of Calyxt's common stock on May 31, 2023. On the closing date, the closing price of Calyxt's common stock was $6.30. Upon closing, Calyxt was renamed \"Cibus, Inc.\", the Issuer's Amended and Restated Certificate was amended such that the Issuer had two classes of common stock (Class A Common Stock and Class B Common Stock), and Calyxt's existing common stock remained as Class A Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held by the Rory Riggs Family Trust, for which the reporting person is trustee and has sole voting and dispositive power with respect to the shares held by the trust."}],"balance_after":851578,"source":{"system":"sec-edgar","filing":"0000899243-23-014329","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000089924323014329/doc4.xml","form_type":"4"}},{"id":1870780,"issuer":{"id":6658,"kind":"organization","name":"Cibus, Inc."},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A Common Stock","published_at":"2023-06-02T11:05:23.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":848662,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of Class A Common Stock received as consideration in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated January 13, 2023, as amended by the First Amendment to the Merger Agreement, dated April 14, 2023 (as amended, the \"Merger Agreement\"), by and among Cibus, Inc. (formerly Calyxt, Inc.) (the \"Issuer\", and prior to the closing of the transactions contemplated by the Merger Agreement, \"Calyxt\"), Calypso Merger Subsidiary, LLC, Cibus Global, LLC (\"Cibus\") and certain blocker entities party thereto."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Gives effect to the 1-for-5 reverse stock split of Calyxt's common stock on May 31, 2023. On the closing date, the closing price of Calyxt's common stock was $6.30. Upon closing, Calyxt was renamed \"Cibus, Inc.\", the Issuer's Amended and Restated Certificate was amended such that the Issuer had two classes of common stock (Class A Common Stock and Class B Common Stock), and Calyxt's existing common stock remained as Class A Common Stock."}],"balance_after":848662,"source":{"system":"sec-edgar","filing":"0000899243-23-014329","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000089924323014329/doc4.xml","form_type":"4"}},{"id":1883233,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2023-05-23T00:36:52.000Z","date":"2023-05-22","kind":"sale","planned":false,"acquired":false,"shares":1750000,"price":32.82,"value":57435000.0,"ownership":{"direct":true},"balance_after":6762,"source":{"system":"sec-edgar","filing":"0001209191-23-031614","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000120919123031614/doc4.xml","form_type":"4"}},{"id":1895591,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2023-05-12T22:43:38.000Z","date":"2023-05-09","kind":"exercise","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with the exchange."},{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with the exchange."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."}],"balance_after":354059,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001209191-23-029216","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000120919123029216/doc4.xml","form_type":"4"}},{"id":1895590,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2023-05-12T22:43:38.000Z","date":"2023-05-09","kind":"exercise","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with the exchange."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with the exchange."}],"balance_after":1756762,"source":{"system":"sec-edgar","filing":"0001209191-23-029216","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000120919123029216/doc4.xml","form_type":"4"}},{"id":1929883,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-04-04T21:01:52.000Z","date":"2023-03-31","kind":"grant","planned":false,"acquired":true,"shares":313,"price":54.15,"value":16948.95,"ownership":{"direct":true},"balance_after":78360,"source":{"system":"sec-edgar","filing":"0001209191-23-022791","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000120919123022791/doc4.xml","form_type":"4"}},{"id":1935198,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2023-03-30T21:53:52.000Z","date":"2023-03-30","kind":"sale","planned":false,"acquired":false,"shares":130024,"price":36.2575,"value":4714345.18,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.22 to $36.30 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1456762,"source":{"system":"sec-edgar","filing":"0001209191-23-021649","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000120919123021649/doc4.xml","form_type":"4"}},{"id":1935197,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2023-03-30T21:53:52.000Z","date":"2023-03-29","kind":"sale","planned":false,"acquired":false,"shares":9926,"price":36.95,"value":366765.7,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.75 to $37.18 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1586786,"source":{"system":"sec-edgar","filing":"0001209191-23-021649","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000120919123021649/doc4.xml","form_type":"4"}},{"id":2008827,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2023-02-17T21:59:29.000Z","date":"2023-02-17","kind":"exercise","acquired":false,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with the exchange."},{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with the exchange."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."}],"balance_after":384059,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":1500000},"source":{"system":"sec-edgar","filing":"0001209191-23-010719","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000120919123010719/doc4.xml","form_type":"4"}},{"id":2008826,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2023-02-17T21:59:29.000Z","date":"2023-02-17","kind":"exercise","acquired":true,"shares":1500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with the exchange."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with the exchange."}],"balance_after":1596712,"source":{"system":"sec-edgar","filing":"0001209191-23-010719","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000120919123010719/doc4.xml","form_type":"4"}},{"id":2073253,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-03T21:18:01.000Z","date":"2022-12-30","kind":"grant","acquired":true,"shares":321,"price":52.92,"value":16987.32,"ownership":{"direct":true},"balance_after":78047,"source":{"system":"sec-edgar","filing":"0001209191-23-000190","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000120919123000190/doc4.xml","form_type":"4"}},{"id":2088616,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2022-12-13T23:20:42.000Z","date":"2002-12-12","kind":"sale","acquired":false,"shares":40010,"price":41.9816,"value":1679683.816,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.90 to $42.07 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":96712,"source":{"system":"sec-edgar","filing":"0001209191-22-061057","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000120919122061057/doc4.xml","form_type":"4"}},{"id":2088615,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2022-12-13T23:20:42.000Z","date":"2022-12-09","kind":"sale","acquired":false,"shares":19990,"price":42.068,"value":840939.32,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.21 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":136722,"source":{"system":"sec-edgar","filing":"0001209191-22-061057","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000120919122061057/doc4.xml","form_type":"4"}},{"id":2109164,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2022-11-21T23:12:01.000Z","date":"2022-11-17","kind":"sale","acquired":false,"shares":120000,"price":42.3327,"value":5079924.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.16 to $42.53 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":156712,"source":{"system":"sec-edgar","filing":"0001209191-22-058252","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000120919122058252/doc4.xml","form_type":"4"}},{"id":2145727,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-04T20:11:11.000Z","date":"2022-09-30","kind":"grant","acquired":true,"shares":365,"price":46.53,"value":16983.45,"ownership":{"direct":true},"balance_after":77726,"source":{"system":"sec-edgar","filing":"0001209191-22-052198","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000120919122052198/doc4.xml","form_type":"4"}},{"id":2158734,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2022-09-15T23:56:17.000Z","date":"2022-09-15","kind":"sale","acquired":false,"shares":52025,"price":42.2097,"value":2195959.6425,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.08 to $42.51 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":276712,"source":{"system":"sec-edgar","filing":"0001209191-22-050172","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000120919122050172/doc4.xml","form_type":"4"}},{"id":2158733,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2022-09-15T23:56:17.000Z","date":"2022-09-14","kind":"sale","acquired":false,"shares":47975,"price":42.406,"value":2034427.85,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.28 to $42.57 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":328737,"source":{"system":"sec-edgar","filing":"0001209191-22-050172","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000120919122050172/doc4.xml","form_type":"4"}},{"id":2188425,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2022-08-11T21:07:54.000Z","date":"2022-08-09","kind":"sale","acquired":false,"shares":45000,"price":43.7294,"value":1967823.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.66 to $43.80 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":376712,"source":{"system":"sec-edgar","filing":"0000899243-22-028395","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000089924322028395/doc4.xml","form_type":"4"}},{"id":2215555,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-05T20:06:18.000Z","date":"2022-06-30","kind":"grant","acquired":true,"shares":289,"price":57.08,"value":16496.12,"ownership":{"direct":true},"balance_after":77361,"source":{"system":"sec-edgar","filing":"0001209191-22-040561","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000120919122040561/doc4.xml","form_type":"4"}},{"id":2219599,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2022-06-29T22:02:48.000Z","date":"2022-06-29","kind":"sale","acquired":false,"shares":30000,"price":42.1746,"value":1265238.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.05 to $42.29 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":421712,"source":{"system":"sec-edgar","filing":"0001209191-22-039839","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000120919122039839/doc4.xml","form_type":"4"}},{"id":2234712,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-13T21:08:35.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":16757,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16757,"derivative":{"exercise_price":55.48,"exercise_date":"2023-06-09","expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":16757},"source":{"system":"sec-edgar","filing":"0001209191-22-036383","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000120919122036383/doc4.xml","form_type":"4"}},{"id":2260623,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2022-05-23T20:55:38.000Z","date":"2022-05-20","kind":"sale","acquired":false,"shares":123696,"price":39.279,"value":4858655.184,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.00 to $40.04 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":451712,"source":{"system":"sec-edgar","filing":"0001209191-22-031363","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000120919122031363/doc4.xml","form_type":"4"}},{"id":2260622,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2022-05-23T20:55:38.000Z","date":"2022-05-19","kind":"sale","acquired":false,"shares":26304,"price":40.0947,"value":1054650.9888,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.29 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":575408,"source":{"system":"sec-edgar","filing":"0001209191-22-031363","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000120919122031363/doc4.xml","form_type":"4"}},{"id":2309442,"issuer":{"id":81206,"kind":"organization","name":"Intra-Cellular Therapies, Inc.","symbol":"ITCI"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-04T20:08:02.000Z","date":"2022-03-31","kind":"grant","acquired":true,"shares":257,"price":61.19,"value":15725.83,"ownership":{"direct":true},"balance_after":77072,"source":{"system":"sec-edgar","filing":"0001209191-22-022314","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000120919122022314/doc4.xml","form_type":"4"}},{"id":2314439,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2022-03-30T22:46:50.000Z","date":"2022-03-29","kind":"sale","acquired":false,"shares":60000,"price":38.5887,"value":2315322.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.51 to $38.74 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":601712,"source":{"system":"sec-edgar","filing":"0001209191-22-021660","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000120919122021660/doc4.xml","form_type":"4"}},{"id":2323539,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2022-03-21T22:20:27.000Z","date":"2022-03-21","kind":"sale","acquired":false,"shares":14322,"price":39.051,"value":559288.422,"ownership":{"direct":false,"nature":"By New Ventures I LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.71 to $39.30 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-22-020333","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000120919122020333/doc4.xml","form_type":"4"}},{"id":2323538,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":41461,"kind":"person","name":"RIGGS RORY B","position":1,"cik":"0001016835","reported_name":"RIGGS RORY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2022-03-21T22:20:27.000Z","date":"2022-03-21","kind":"sale","acquired":false,"shares":25545,"price":39.051,"value":997557.795,"ownership":{"direct":false,"nature":"By New Ventures Select"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.71 to $39.30 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-22-020333","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1016835/000120919122020333/doc4.xml","form_type":"4"}}],"next_cursor":"2022-03-21T22:20:27.000000Z,2323538"}